SMT202200447T1 - Composizioni oftalmiche comprendenti un antagonista muscarinico e acqua deuterata - Google Patents

Composizioni oftalmiche comprendenti un antagonista muscarinico e acqua deuterata

Info

Publication number
SMT202200447T1
SMT202200447T1 SM20220447T SMT202200447T SMT202200447T1 SM T202200447 T1 SMT202200447 T1 SM T202200447T1 SM 20220447 T SM20220447 T SM 20220447T SM T202200447 T SMT202200447 T SM T202200447T SM T202200447 T1 SMT202200447 T1 SM T202200447T1
Authority
SM
San Marino
Prior art keywords
ophthalmic compositions
muscarinic antagonist
deuterated water
deuterated
water
Prior art date
Application number
SM20220447T
Other languages
English (en)
Italian (it)
Inventor
Gregory I Ostrow
Kenneth J Widder
David S Baker
Original Assignee
Sydnexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202200447(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sydnexis Inc filed Critical Sydnexis Inc
Publication of SMT202200447T1 publication Critical patent/SMT202200447T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20220447T 2014-06-24 2015-06-23 Composizioni oftalmiche comprendenti un antagonista muscarinico e acqua deuterata SMT202200447T1 (it)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462016502P 2014-06-24 2014-06-24
US201462096433P 2014-12-23 2014-12-23
US201562151926P 2015-04-23 2015-04-23
US14/726,139 US9421199B2 (en) 2014-06-24 2015-05-29 Ophthalmic composition
EP15811865.3A EP3160471B1 (en) 2014-06-24 2015-06-23 Ophthalmic compositions comprising a muscarinic antagonist and deuterated water
PCT/US2015/037249 WO2015200361A1 (en) 2014-06-24 2015-06-23 Ophthalmic composition

Publications (1)

Publication Number Publication Date
SMT202200447T1 true SMT202200447T1 (it) 2023-01-13

Family

ID=54868660

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220447T SMT202200447T1 (it) 2014-06-24 2015-06-23 Composizioni oftalmiche comprendenti un antagonista muscarinico e acqua deuterata

Country Status (22)

Country Link
US (12) US9421199B2 (enExample)
EP (3) EP3160471B1 (enExample)
JP (5) JP6678362B2 (enExample)
KR (4) KR20240144477A (enExample)
CN (3) CN106572998B (enExample)
BR (1) BR112016030368B1 (enExample)
CA (1) CA2953363C (enExample)
DK (1) DK3160471T3 (enExample)
ES (1) ES2924243T3 (enExample)
FI (1) FIC20250034I1 (enExample)
HR (1) HRP20220972T1 (enExample)
HU (1) HUE059521T2 (enExample)
IL (1) IL249643B (enExample)
LT (1) LT3160471T (enExample)
PL (1) PL3160471T3 (enExample)
PT (1) PT3160471T (enExample)
RS (1) RS63486B1 (enExample)
SG (3) SG11201610682UA (enExample)
SI (1) SI3160471T1 (enExample)
SM (1) SMT202200447T1 (enExample)
TW (4) TW202510877A (enExample)
WO (1) WO2015200361A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980839B2 (en) 2012-08-24 2015-03-17 Ocular Technologies Sarl Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
HK1248570A1 (zh) * 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
WO2017177262A1 (en) 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
AR108591A1 (es) * 2016-05-25 2018-09-05 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
US11253507B2 (en) * 2017-02-21 2022-02-22 Singapore Health Services Ptd Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
CN110505876A (zh) * 2017-03-23 2019-11-26 新加坡保健服务集团 包含噻托铵作为活性成分的用于预防近视、治疗近视、及/或预防近视进展的药剂
IL315639A (en) 2017-03-27 2024-11-01 Regeneron Pharma Sterilization method
EP3548000B1 (en) * 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
AU2018279940B2 (en) 2017-06-10 2023-12-14 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
US11285141B2 (en) 2017-07-20 2022-03-29 Seinda Pharmaceutical Guangzhou Corporation Composition and methods for the treatment of myopia
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
AU2019205774B2 (en) 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
CN109157503B (zh) * 2018-09-25 2019-08-16 沈阳兴齐眼药股份有限公司 防治nitm的药物组合物及其医药用途
CN110934816B (zh) * 2018-09-25 2022-04-08 沈阳兴齐眼科医院有限公司 一种提高低浓度阿托品眼用制剂稳定性的方法
SG11202108457UA (en) * 2019-02-06 2021-09-29 Tearclear Corp Systems and methods for preservative removal from ophthalmic formulations comprising complexing agents
EP3701938B8 (en) 2019-03-01 2024-02-21 Medivis S.R.L. Ophthalmic formulations based on atropine
EP3946256B1 (en) * 2019-03-26 2024-07-17 Aura Biosciences, Inc. Virus-like particle formulations
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
WO2021007578A1 (en) * 2019-07-11 2021-01-14 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
CA3158243A1 (en) * 2019-11-15 2021-07-15 Brian D. Lawrence Stable formulations of silk-derived protein
CA3164288A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
IL293859A (en) * 2019-12-16 2022-08-01 Sydnexis Inc Ophthalmic compositions comprising d2o
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
US20220031625A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
KR102245533B1 (ko) * 2020-11-02 2021-04-28 주식회사 지게차코리아 운송수단용 림 및 이의 제조방법
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations
KR20230142548A (ko) 2021-02-03 2023-10-11 에이디에스 테라퓨틱스 엘엘씨 국소 안과용 조성물
CA3205883A1 (en) * 2021-02-04 2022-08-11 Gregory I. Ostrow Ophthalmic compositions for presbyopia
WO2022172089A1 (en) * 2021-02-12 2022-08-18 I Optima Ltd. Compound, method and system for ophthalmic surgery
CA3211874A1 (en) * 2021-03-16 2022-09-22 Kumaresh Soppimath Multi-dose container for ophthalmic compositions
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
US12310474B2 (en) 2021-10-08 2025-05-27 Johnson & Johnson Vision Care, Inc. Multi-material lens package
EP4426353A2 (en) * 2021-11-05 2024-09-11 Calm Water Therapeutics LLC Methods for using bioadhesive and steric interactions of copolymers to minimize adverse effects
US20250186415A1 (en) * 2022-03-07 2025-06-12 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023171989A1 (ko) * 2022-03-11 2023-09-14 주식회사 메디치바이오 안질환 예방 또는 치료용 약학 조성물
WO2023215407A2 (en) * 2022-05-03 2023-11-09 Iview Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
EP4555375A1 (en) 2022-07-15 2025-05-21 Praful Doshi Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs
US20240033260A1 (en) * 2022-07-26 2024-02-01 The Chinese University Of Hong Kong Low-concentration atropine for myopia prevention (lamp-2) study
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
CN121079085A (zh) * 2023-03-16 2025-12-05 格劳科斯公司 眼科乳膏剂制剂及其用途
TW202525288A (zh) * 2023-10-26 2025-07-01 英商庫博光學國際有限公司 液體組合物

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (enExample) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
AU7528696A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
JP2000509971A (ja) 1996-04-10 2000-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 化学的シャペローンを用いる遺伝的欠陥の修正
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (enExample) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
AU779783B2 (en) 1999-05-17 2005-02-10 Eisai Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
AU2001278779A1 (en) 2000-08-25 2002-03-04 Senju Pharmaceutical Co. Ltd. Aqueous suspension preparations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
PL366924A1 (en) 2001-05-25 2005-02-07 Valley Forge Pharmaceuticals, Inc. Pirenzepine ophthalmic gel
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
JP2007502823A (ja) 2003-08-15 2007-02-15 キューエルティー・ユーエスエイ・インコーポレーテッド 接着性および生体侵食性の経粘膜薬物送達システム
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2007519496A (ja) 2004-01-27 2007-07-19 オステオテック，インコーポレイテッド 安定化された骨移植片
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
US8349351B2 (en) 2005-02-04 2013-01-08 Auburn University Contact drug delivery system
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
EP1954254A4 (en) 2005-11-01 2010-12-22 Harvard College MODULATION OF THE LOADING OF THE ENDOPLASMIC RETICULUM IN THE TREATMENT OF TUBEROUS SCLEROSIS
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) * 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) * 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
MX2010003774A (es) * 2007-10-08 2010-04-27 Fovea Pharmaceuticals Sa Formulaciones oftalmicas acuosas.
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) * 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
ES2459198T3 (es) 2008-04-20 2014-05-08 D2 Bioscience Group Ltd Utilización de óxido de deuterio como inhibidor de elastasa
US8414912B2 (en) 2008-12-11 2013-04-09 Massachusetts Institute Of Technology Contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
US8883214B2 (en) 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
US20120203161A1 (en) * 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
KR20130111932A (ko) * 2010-04-30 2013-10-11 세로스 메디컬, 엘엘씨 조합 방식을 이용하여 안구 조직을 치료하는 방법 및 장치
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
CA2805426C (en) 2010-07-15 2020-03-24 Corinthian Ophthalmic, Inc. Drop generating device
JP2013531044A (ja) 2010-07-15 2013-08-01 コリンシアン オフサルミック，インコーポレイティド 点眼薬送達
JP5823766B2 (ja) * 2010-07-30 2015-11-25 大塚製薬株式会社 医薬組成物
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
WO2012111029A2 (en) * 2011-02-18 2012-08-23 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
CN103491945A (zh) 2011-03-03 2014-01-01 阿勒根公司 基于硅酮的非水性眼科制剂
JP6148664B2 (ja) 2011-04-05 2017-06-14 オプトソルヴ リサーチ アンド ディベロップメント リミテッド 眼科治療
CA2835343A1 (en) 2011-05-12 2012-11-15 Foresight Biotherapeutics, Inc. Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
ES2639832T3 (es) 2011-11-29 2017-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones farmacéuticas para el tratamiento de la enfermedad de Darier
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
US20130303627A1 (en) * 2012-02-27 2013-11-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
AU2013257830A1 (en) 2012-05-11 2014-11-20 Cipla Limited Pharmaceutical composition
SG11201407428YA (en) 2012-05-14 2014-12-30 Eyenovia Inc Laminar flow droplet generator device and methods of use
SG10201602609XA (en) 2012-05-15 2016-05-30 Eyenovia Inc Ejector devices, methods, drivers, and circuits therefor
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
US8980839B2 (en) 2012-08-24 2015-03-17 Ocular Technologies Sarl Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
WO2014161002A2 (en) 2013-03-29 2014-10-02 Onefocus Technology, Llc Drug delivery from contact lenses with a fluidic module
KR102027663B1 (ko) 2013-05-06 2019-10-01 가오슝 창 궁 메모리얼 하스피털 약학적 조성물 및 이의 용도
PT4275756T (pt) 2013-05-17 2025-10-31 Incyte Holdings Corp Derivados de bipirazole como inibidores da jak
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US10123904B2 (en) 2014-08-13 2018-11-13 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
AR108591A1 (es) 2016-05-25 2018-09-05 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
EP3607936B1 (en) 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
US11253507B2 (en) 2017-02-21 2022-02-22 Singapore Health Services Ptd Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
EP3548000B1 (en) 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
US11285141B2 (en) 2017-07-20 2022-03-29 Seinda Pharmaceutical Guangzhou Corporation Composition and methods for the treatment of myopia
US20200345542A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
IL293859A (en) 2019-12-16 2022-08-01 Sydnexis Inc Ophthalmic compositions comprising d2o

Also Published As

Publication number Publication date
EP3160471B1 (en) 2022-06-01
US10842787B2 (en) 2020-11-24
HUE059521T2 (hu) 2022-11-28
US11890277B2 (en) 2024-02-06
CA2953363A1 (en) 2015-12-30
US20180193326A1 (en) 2018-07-12
TWI763620B (zh) 2022-05-11
BR112016030368A2 (pt) 2018-07-17
CN106572998B (zh) 2019-11-08
US11596625B2 (en) 2023-03-07
DK3160471T3 (da) 2022-08-15
US11382909B2 (en) 2022-07-12
RS63486B1 (sr) 2022-09-30
JP2024050526A (ja) 2024-04-10
TWI855319B (zh) 2024-09-11
LT3160471T (lt) 2022-11-10
EP3689350A1 (en) 2020-08-05
HRP20220972T1 (hr) 2022-11-25
ES2924243T3 (es) 2022-10-05
CN115192520A (zh) 2022-10-18
PL3160471T3 (pl) 2022-09-26
KR102710491B1 (ko) 2024-09-25
CN110638749A (zh) 2020-01-03
US9770447B2 (en) 2017-09-26
US9421199B2 (en) 2016-08-23
US20180042911A1 (en) 2018-02-15
CA2953363C (en) 2024-02-27
US20200085813A1 (en) 2020-03-19
JP2025131595A (ja) 2025-09-09
US20230093205A1 (en) 2023-03-23
US20150366854A1 (en) 2015-12-24
EP3160471A4 (en) 2018-04-04
TW201613588A (en) 2016-04-16
WO2015200361A1 (en) 2015-12-30
JP7505888B2 (ja) 2024-06-25
IL249643A0 (en) 2017-02-28
PT3160471T (pt) 2022-08-09
SG10201913976SA (en) 2020-03-30
US20190298707A1 (en) 2019-10-03
JP6678362B2 (ja) 2020-04-08
KR20200001612A (ko) 2020-01-06
US20240165098A1 (en) 2024-05-23
SG11201610682UA (en) 2017-01-27
KR102506109B1 (ko) 2023-03-03
BR112016030368B1 (pt) 2022-11-01
KR20240144477A (ko) 2024-10-02
US20190091213A1 (en) 2019-03-28
KR20170018962A (ko) 2017-02-20
TWI867694B (zh) 2024-12-21
US11896588B2 (en) 2024-02-13
JP2022062045A (ja) 2022-04-19
US20210213008A9 (en) 2021-07-15
TW202510877A (zh) 2025-03-16
US20230092957A1 (en) 2023-03-23
CN106572998A (zh) 2017-04-19
EP3160471A1 (en) 2017-05-03
SI3160471T1 (sl) 2022-10-28
US10201534B2 (en) 2019-02-12
US10076515B2 (en) 2018-09-18
SG10201707617VA (en) 2017-10-30
US20160339007A1 (en) 2016-11-24
KR20210116688A (ko) 2021-09-27
TW202412797A (zh) 2024-04-01
US11883390B2 (en) 2024-01-30
JP2017522292A (ja) 2017-08-10
US20210059998A1 (en) 2021-03-04
EP4115884A1 (en) 2023-01-11
TW202237110A (zh) 2022-10-01
FIC20250034I1 (fi) 2025-11-28
US20230091109A1 (en) 2023-03-23
IL249643B (en) 2021-10-31
JP2020097599A (ja) 2020-06-25
US10864208B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
SMT202200447T1 (it) Composizioni oftalmiche comprendenti un antagonista muscarinico e acqua deuterata
IL280791A (en) Deuterium compounds and their use
ZA201801678B (en) Deuterated compounds and uses thereof
PL3102634T3 (pl) Miękkie i przezroczyste kopolimery odporne na uderzenia
ZA201703805B (en) Low water dentifrice compositions
IL251059B (en) Arimoclomol formulation
ZA201703804B (en) Cleansing compositions
IL257167A (en) Antitussive compositions and methods
GB201411134D0 (en) Ocular simulation tool
GB2537548B (en) Set-delayed cement compositions comprising pumice and associated methods
GB201407079D0 (en) Complete flood protection
IL251590A0 (en) Ophthalmic preparations
ZA201703701B (en) Ophthalmic composition
GB201413538D0 (en) Ophthalmic compositions and uses thereof
TWI562749B (en) Soap placement device
GB2529914B (en) Hand protection device
GB201508876D0 (en) Sanitary protection
GB201404391D0 (en) Novel compositions having use in therapy
GB201407024D0 (en) Dental caddy
GB201408619D0 (en) Tri-lock integrated fence